Matches in SemOpenAlex for { <https://semopenalex.org/work/W2216135087> ?p ?o ?g. }
Showing items 1 to 74 of
74
with 100 items per page.
- W2216135087 endingPage "15545" @default.
- W2216135087 startingPage "15545" @default.
- W2216135087 abstract "15545 Background: Inhibitors of the VEGF pathway have been shown to have activity in neuroendocrine tumors (NET). Oxaliplatin- based chemotherapy also shows limited activity in this disease. We performed a prospective, phase II study to assess the safety and efficacy of mFOLFOX-6 plus bevacizumab (BV) in patients (pts) with advanced, progressive NET. Methods: Pts with carcinoid tumors (CARC), pancreatic NET (PNET), or platinum-refractory poorly differentiated (anaplastic, small- or large-cell) NET (PDNET) were enrolled using a Simon 2- stage design (3 groups). Eligibility criteria included clinical or radiologic evidence of progression, no prior anti-VEGF therapy, and no varices secondary to splenic vein thrombosis. Treatment consisted of mFOLFOX-6 plus BV (5 mg/kg IV) every 14 days (1 cycle = 2 weeks). Pts were followed for toxicity and response. Results: 13 pts with progressive NET have been enrolled: M/F=9/4; median age=60 (range 43–73); ECOG PS 0/1= 7/6; CARC/PNET/PDNET= 6/6/1. Pts on octreotide remained on the drug. Pts have received treatment for a median of 11 cycles (range 3–26). Grade 3–4 toxicities included: abdominal pain (15.4%), anemia (15.3%), neutropenia (30.8%), febrile neutropenia (7.6%), fatigue (38.4%), ascites (7.6%), gastrointestinal hemorrhage (7.6%), hypertension (23%), thrombocytopenia (7.6%), diarrhea (7.6%) and peripheral sensory neuropathy (15.3%). There was 1 arterial thromboembolic event (penetrating ulcer-thoracic aorta) and 1 treatment- related death from sepsis (in setting of neutropenia, diarrhea, and probable GI perforation). Of 9 pts with an elevated chromogranin at baseline; 4 pts demonstrated >50% decline (1 CARC, 3 PNET). One pt with metastatic insulinoma requiring home dextrose infusions experienced a >50% reduction in insulin levels and marked clinical improvement. 12 pts are evaluable for best radiologic response (by RECIST, confirmed): CARC 1/5 PR (20%), 4/5 SD (80%); PNET 2/6 PR (33%), 4/6 SD (67%); PDNET 1/1 SD. Conclusions: The combination of FOLFOX plus BV shows promising activity in pts with advanced, progressive NET. However, the toxicity profile suggests that careful pt selection may be important. Enrollment to this study continues. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Genentech™ BioOncology, sanofi-aventis Genentech™ BioOncology, sanofi-aventis" @default.
- W2216135087 created "2016-06-24" @default.
- W2216135087 creator A5017353771 @default.
- W2216135087 creator A5033960518 @default.
- W2216135087 creator A5037875642 @default.
- W2216135087 creator A5056858207 @default.
- W2216135087 creator A5072641295 @default.
- W2216135087 creator A5075546945 @default.
- W2216135087 creator A5089128754 @default.
- W2216135087 date "2008-05-20" @default.
- W2216135087 modified "2023-09-27" @default.
- W2216135087 title "Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors" @default.
- W2216135087 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.15545" @default.
- W2216135087 hasPublicationYear "2008" @default.
- W2216135087 type Work @default.
- W2216135087 sameAs 2216135087 @default.
- W2216135087 citedByCount "36" @default.
- W2216135087 countsByYear W22161350872012 @default.
- W2216135087 countsByYear W22161350872013 @default.
- W2216135087 countsByYear W22161350872014 @default.
- W2216135087 countsByYear W22161350872015 @default.
- W2216135087 countsByYear W22161350872016 @default.
- W2216135087 countsByYear W22161350872017 @default.
- W2216135087 countsByYear W22161350872018 @default.
- W2216135087 countsByYear W22161350872019 @default.
- W2216135087 countsByYear W22161350872020 @default.
- W2216135087 countsByYear W22161350872021 @default.
- W2216135087 crossrefType "journal-article" @default.
- W2216135087 hasAuthorship W2216135087A5017353771 @default.
- W2216135087 hasAuthorship W2216135087A5033960518 @default.
- W2216135087 hasAuthorship W2216135087A5037875642 @default.
- W2216135087 hasAuthorship W2216135087A5056858207 @default.
- W2216135087 hasAuthorship W2216135087A5072641295 @default.
- W2216135087 hasAuthorship W2216135087A5075546945 @default.
- W2216135087 hasAuthorship W2216135087A5089128754 @default.
- W2216135087 hasConcept C126322002 @default.
- W2216135087 hasConcept C141071460 @default.
- W2216135087 hasConcept C2776694085 @default.
- W2216135087 hasConcept C2777063308 @default.
- W2216135087 hasConcept C2777802072 @default.
- W2216135087 hasConcept C2779066768 @default.
- W2216135087 hasConcept C2780955771 @default.
- W2216135087 hasConcept C71924100 @default.
- W2216135087 hasConcept C90924648 @default.
- W2216135087 hasConceptScore W2216135087C126322002 @default.
- W2216135087 hasConceptScore W2216135087C141071460 @default.
- W2216135087 hasConceptScore W2216135087C2776694085 @default.
- W2216135087 hasConceptScore W2216135087C2777063308 @default.
- W2216135087 hasConceptScore W2216135087C2777802072 @default.
- W2216135087 hasConceptScore W2216135087C2779066768 @default.
- W2216135087 hasConceptScore W2216135087C2780955771 @default.
- W2216135087 hasConceptScore W2216135087C71924100 @default.
- W2216135087 hasConceptScore W2216135087C90924648 @default.
- W2216135087 hasIssue "15_suppl" @default.
- W2216135087 hasLocation W22161350871 @default.
- W2216135087 hasOpenAccess W2216135087 @default.
- W2216135087 hasPrimaryLocation W22161350871 @default.
- W2216135087 hasRelatedWork W2003938723 @default.
- W2216135087 hasRelatedWork W2047967234 @default.
- W2216135087 hasRelatedWork W2118496982 @default.
- W2216135087 hasRelatedWork W2364998975 @default.
- W2216135087 hasRelatedWork W2439875401 @default.
- W2216135087 hasRelatedWork W3209898221 @default.
- W2216135087 hasRelatedWork W4238549103 @default.
- W2216135087 hasRelatedWork W4238867864 @default.
- W2216135087 hasRelatedWork W4380186280 @default.
- W2216135087 hasRelatedWork W2525756941 @default.
- W2216135087 hasVolume "26" @default.
- W2216135087 isParatext "false" @default.
- W2216135087 isRetracted "false" @default.
- W2216135087 magId "2216135087" @default.
- W2216135087 workType "article" @default.